Quercetin

Where the papers sit

59 papers from the last 6 months study quercetin directly · updated from PubMed 5 Oct 2026

• Network Pharmacology of Quercetin

  Network pharmacology is positioning quercetin as a multitarget candidate across cancer, ulcerative, neurodegenerative and inflammatory disorders. Predicted protein networks and docking results are increasingly paired with PCR, omics or animal validation rather than left as computational hypotheses. Recurrent mechanisms include oxidative stress control, lipid metabolism, inflammatory signaling and regulated cell death. Disease contexts remain diverse, so shared molecular targets are more consistent than any single clinical indication.

  16 papers · 27.1%

• Oxidative Stress and Senescence

  Oxidative stress and cellular senescence recur as targets across metabolic, inflammatory, neurologic and reproductive disease models. Quercetin and related phytochemicals are being used to reduce senescence-associated dysfunction, restore antioxidant defenses and limit tissue injury. Nanoparticles and herbosomal systems are moving these compounds toward organ-specific delivery, including the colon and brain. Mechanistic evidence remains divided among redox control, inflammatory signaling and mitochondrial protection.

  13 papers · 22%

• Mitochondrial Oxidative Stress

  Mitochondrial oxidative stress links the cluster’s work on rheumatoid arthritis, bone erosion, stroke, cardiac injury and tissue repair. Quercetin is being shifted from generic antioxidant claims toward mitophagy, microglial modulation and defined inflammatory pathways such as Wnt3a/β-catenin and MAPK/NF-κB. Nanoparticles, hydrogels and self-assembled carriers seek to concentrate activity at damaged tissues. Benefits remain model-dependent, and one cardiac study found redox improvement without restored mitochondrial respiration.

  12 papers · 20.3%

• Natural Compound Therapeutics

  Natural compounds are being advanced through computational screening, delivery engineering and early biological testing. Molecular docking and kinetic modelling nominate targets in lung cancer, antimicrobial resistance and microbial virulence. Nanocarriers, invasomal gels and PEG 400 strategies aim to improve quercetin solubility, permeability and bioavailability. Evidence remains heterogeneous, spanning in vitro activity, formulation studies and limited animal or pharmacokinetic validation.

  9 papers · 15.3%

• Drug Delivery and Bioavailability

  Formulation work is focused on overcoming quercetin’s poor solubility, permeability and stability. Pickering emulsions, PAMAM dendrimers, niosomes and block-copolymer micelles are being tuned for amorphization, controlled release and improved tissue exposure. Electron and polarized-light microscopy, alongside dissolution and permeability assays, provide the recurring characterization framework. Clinical evidence is still limited, with atopic dermatitis cream studies offering a rare move beyond physicochemical optimization.

  5 papers · 8.5%

• Apoptosis in Tissue Injury

  Apoptosis is being treated as context-dependent: suppressed to protect skeletal muscle, but induced to eliminate cancer cells. BCL2, BAX and CASP3 recur alongside oxidative stress and autophagy in muscle injury. Gastric cancer work adds PI3K-AKT modulation and improved T-cell immunity. The main unresolved issue is how to separate tissue protection from pro-apoptotic anticancer activity.

  4 papers · 6.8%